Replies to post #180727 on Biotech Values

[DewDiligence]

ENTA’s decision whether to opt-in for US profit-sharing on the ABT-493/ABT-530 regimen is likely to be made during September, based on comments from today’s Baird webcast. (See #msg-104670740 for background.)

[DewDiligence]

ABBV/ENTA start phase-2b trial of pan-genotypic qD 2-DAA regimen of ABT-493+ABT-530:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-initiation-phase-142200069.html